An open label, single-dose midazolam, multiple-dose HCV-796, sequential 3-period study to determine the pharmacokinetics of the potential drug interaction between HCV-796 and midazolam

Trial Profile

An open label, single-dose midazolam, multiple-dose HCV-796, sequential 3-period study to determine the pharmacokinetics of the potential drug interaction between HCV-796 and midazolam

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2008

At a glance

  • Drugs Nesbuvir (Primary) ; Midazolam
  • Indications Anxiety disorders; Hepatitis C; Seizures
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 16 Apr 2008 Development of nesbuvir has been discontinued due to safety issues, according to a ViroPharma media release.
    • 11 Oct 2007 Status changed from recruiting to completed.
    • 26 Jun 2007 Status change from initiated to recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top